Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in early polymyalgia rheumatica
NL-OMON61252Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of sarilumab and prednisone in polymyalgia rheumatica (PMR) (3 arms), sponsored by Sanofi. Primary endpoint: Sustained remission at Week 52. Started Sep 2026; status: recruiting.
02
Drugs
sarilumabprednisone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON61252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61252.